Abstract
The olfactory pathway is composed of peripheral sinonasal and central sensorineural components. The wide variety of different pathologies that can affect the olfactory pathway reflect this complex anatomical relationship. Localising olfactory pathology can present a challenge to the reporting radiologist. This imaging review will illustrate the normal anatomy of the olfactory system and describe a systematic approach to considering olfactory dysfunction. Key concepts in image interpretation will be demonstrated using examples of olfactory pathway pathologies.
Keywords: Olfactory, Olfactory bulb, Olfactory tract, CT, MRI
Key points
Olfactory dysfunction is a prevalent and common complaint.
The olfactory system is composed of peripheral and central components.
CT provides assessment of peripheral sinonasal olfactory disease and bone-related pathology.
MRI provides soft tissue characterisation and intracranial assessment.
CT and MRI are complementary in characterising olfactory system lesions.
Background
Olfactory dysfunction is a common symptom affecting approximately 20% of the general population [1]. Moreover, a significant number of patients presenting with loss of taste sensation have olfactory rather than gustatory deficits [2]. Olfactory dysfunction ranges from reduced smell detection (“hyposmia”) to complete loss of smell (“anosmia”). It also encompasses an abnormal sense of smell (“dysnomia”)—including loss of smell intensity (“parosmia”), inability to recognise smells (“cacosmia”) and olfactory hallucinations (“phantosmia”). Deficits in olfactory function can have a profound impact upon an individual’s overall quality of life and can also affect one’s ability to identify environmental hazards with important safety implications [3].
The olfactory nerves (Cranial Nerve I) and the olfactory pathways connect the peripheral nasal cavity with the central intracranial olfactory system. Olfactory dysfunction can be broadly divided into peripheral conductive and central sensorineural pathologies. Processes that impair the peripheral conduction of odour particles to the olfactory epithelium include sinonasal inflammatory disease and obstructive sinonasal mass lesions. Disruption of olfactory neuronal function and the central olfactory pathways can be secondary to a spectrum of postviral, traumatic, congenital, and neurodegenerative aetiologies. This article will review the normal anatomy of the olfactory pathways, the CT and MR imaging techniques available to image different components of the olfactory pathway, and highlight the spectrum of olfactory system pathologies.
Functional anatomy and imaging of the olfactory pathway
Aromatic molecules within the air are inspired and directed to the posterosuperior region of each nasal cavity, to the olfactory neuroepithelium [4]. The olfactory neuroepithelium is made up of approximately 6–10 million neurons, occupying an area of 2.5cm2 [5]. The neurons combine to form nerve fascicles called fila olfactoria, which together form the first-order olfactory nerves. These first-order olfactory nerves serve as the interface between the peripheral and central olfactory systems. They ascend intracranially across the anterior cranial fossa via multiple perforations in the cribriform plate [4] (Figs. 1, 2). The fila olfactoria are normally difficult to discern on routine 1.5 T imaging, but are identifiable on higher magnetic field 3 T MRI [6].
The first-order olfactory nerve neurons synapse with second-order neurons within the ventral surface of the olfactory bulb, at the base of the frontal lobes. The two olfactory bulbs are located within the olfactory grooves and are surrounded by cerebral spinal fluid (CSF) [7]. They run a parallel course projecting posteriorly (Fig. 3). The olfactory tracts are a continuation of the olfactory bulbs, transmitting the second-order neurons. The olfactory tracts lie within the olfactory sulcus between the gyrus rectus medially and the orbital gyrus laterally (Fig. 1) [4]. The olfactory bulb measures 11–15 mm in length and 4–5 mm in width. The olfactory tract is longer, measuring up to 30 mm and tapering in width from 5 to 2 mm as it passes posteriorly [7]. Olfactory bulb volume correlates with olfactory function [8]. Experimental in vitro cadaveric imaging of the olfactory bulb using 9.4 T MR-microscopy has managed to identify six separate signal intensity layers representing the distinct cellular lamination pattern of the olfactory bulb [9].
The olfactory tracts containing the second-order neurons pass superolaterally over the optic nerves and suprasellar cistern, terminating at the olfactory trigone which lies just above the anterior clinoid process [4]. These second-order neurones then enter the olfactory striae (medial, lateral and intermediate) and then project into the mesial temporal lobe. The mesial temporal lobe houses the central olfactory regions including the entorhinal cortex, piriform cortex, amygdala, and the parahippocampus (Fig. 3) [7]. There are myriad interconnections between these central olfactory regions and the rest of the brain parenchyma, including the mediodorsal thalamus, orbitofrontal cortex, temporal cortex and other regions of the limbic system. This vast network of intracerebral connections enables one’s sense of smell to be intimately integrated with taste, memories, and emotions [4].
Imaging
CT and MRI provide complimentary information in imaging the olfactory pathway [6]. CT is typically the initial imaging modality for suspected “conductive” olfactory problems, in order to identify sinonasal pathology that limits the interaction between aromatic molecules and the olfactory epithelium [10]. At our institution, axial non-contrast CT is performed through the sinonasal compartment and anterior skull base at 0.75–1-mm slice thickness to enable multiplanar reformats in both the sagittal and coronal planes. CT provides the exquisite bony detail required for assessment of the integrity of the ethmoid roof and anterior skull base and enables the exclusion of intrinsic skull pathologies or secondary skull involvement due to other disease processes (Fig. 2). This includes evaluation of bone remodelling and/or destruction associated with inflammatory processes or tumours [11]. Conventional CT imaging, as opposed to cone beam CT imaging, also provides soft tissue information that allows assessment of the sinonasal contents, extracranial soft tissues, and intracranial contents.
MR imaging enables more detailed soft tissue assessment of both the peripheral and central components of the olfactory pathways [6, 12]. At our institution, the MR imaging protocol for olfactory dysfunction includes coronal T2 and T1 weighted imaging with a slice thickness of 2 mm covering the sinonasal compartment, anterior skull base, and anterior cranial fossa contents (Fig. 1). The coronal T2 imaging enables assessment of volume and signal change within the olfactory bulbs and tracts. If there is concern regarding a potential CSF leak, an additional gradient echo CISS (constructive interference in steady state) sequence to cover the anterior skull base is performed, with volumetric 1-mm slices acquired to enable multiplanar reformation. Additional contrast enhanced and diffusion weighted imaging may be necessary to aid differentiation between benign and malignant sinonasal pathologies [10]. The routine imaging protocol includes axial T2 brain imaging to assess the limbic and mesial temporal lobe structures as well as volumetric and coronal T2 and/or FLAIR imaging of the temporal lobes as per standard epilepsy protocols. If there is a prior history of trauma, gradient recall echo- or preferably susceptibility weighted imaging- is also acquired [6].
Peripheral sinonasal compartment pathology
Pathology within the nasal cavity can obstruct the passage of air to the receptors of the olfactory epithelium and can also cause inflammation of the olfactory epithelium. Both of these processes can lead to olfactory disturbance [6, 13]
The sinonasal compartment should normally be air-filled; opacification of the sinonasal compartments on CT suggests the presence of underlying disease processes [14]. In the setting of abnormal sinonasal opacification, evaluation of the surrounding bone architecture is essential to identify any suspicious bony destruction that may portend an aggressive and potentially malignant process [12]. Bony expansion with thinning (termed “rarefaction”), or remodelling with thickening of the bone, both suggests a slow, progressive, and usually benign process (Fig. 4a). The density of the opacification on CT can also help discriminate between various pathologies. Hyperdense opacification suggests benign disease such as inspissated secretions in sinusitis, fungal elements in non-invasive allergic fungal sinusitis, or blood in the context of trauma. The exception is hypervascular tumours such as melanoma, as these can bleed [12]. Hypodensity on CT represents either secretions or malignancy, which can be distinguished on MRI [15].
MRI assists in differentiation between solid soft tissue elements of a tumour and the fluid characteristics of secretions. Secretions are T2 hyperintense and T1 hypointense, whereas primary sinonasal neoplasms are usually T2 intermediate- or less commonly T2 hyperintense- and T1 hypointense [15] (Fig. 5). Post-contrast MR imaging aids in delineation of sinonasal soft tissue masses. Solid components of sinonasal tumours enhance, whilst the haemorrhagic, necrotic, or cystic components do not. Sinonasal tumours can be differentiated from thickened mucosa (peripheral enhancement) and secretions (which do not enhance) based on their enhancement patterns (Fig. 5) [14].
MRI is best suited for demonstrating any transpatial spread of sinonasal disease, including intracranial spread [12]. This includes perineural spread of disease, seen particularly in adenoid cystic carcinoma and squamous cell carcinoma [12]. This is demonstrated on MRI as nerve thickening and/or enhancement, and loss of perineural fat [16]. Widening of the neural foramina may also be seen, especially foramina relating to branches of the trigeminal nerve [17]. Orbital and anterior skull base invasion in both malignant and infective conditions are also best seen on MRI [16]. On coronal imaging, loss of the normal low signal anterior skull base cortical margin, loss of the normal T1 hyperintense marrow signal, and frank breach of the anterior cranial fossa on post-contrast T1WI (Fig. 6) are sensitive indicators of bone infiltration and transcalvarial spread of disease [15].
Benign inflammatory diseases
Sinonasal polyposis is a benign inflammatory mucosal condition that most commonly affects the maxillary sinuses and often extends into the middle meatus of the nasal cavity (Fig. 7). It is characterised by its rounded contours. The presence of more extensive sinonasal polyposis, particularly in the upper meatus and the posterior portion of the middle meatus, can significantly impede olfactory function [18].
Chronic rhinosinusitis is common, and the severity of chronic sinusitis is correlated with reduced olfactory bulb volumes [13]. Sinonasal polyposis often coexists with chronic rhinosinusitis. The role of CT is to assess the pattern of sinonasal drainage impairment, to guide potential endoscopic approach [16]. Prompt diagnosis allows for early treatment which can increase olfactory bulb volumes and improve the patient’s sense of smell [19]. Mucosal thickening and sinus opacification can occur in both acute and chronic sinusitis. The presence of an air-fluid level distinguishes the acute form from the chronic form [15, 16].
Fungal sinusitis can be either non-invasive (subcategorised as allergic or fungal ball/mycetoma forming) or invasive (subcategorised as acute invasive, chronic invasive, or the very infrequently occurring chronic granulomatous) [20]. Allergic non-invasive fungal sinusitis is most common. Although olfactory dysfunction is not considered part of the diagnostic criteria, patients can experience significant olfactory disturbance [21]. It is characterised by the presence of hyperdense serpiginous fungal elements (which can even be calcified) completely opacifying and expanding/remodelling the sinus [21].
Acute invasive fungal sinusitis conversely is potentially life-threatening and occurs in immunocompromised patients. It has a propensity for the ethmoid air cells and sphenoid sinuses [20]. Invasion and obliteration of the periantral, pterygopalatine, or orbital apex fat (Fig. 8) portend life-threatening intracranial spread [20]. Invasive features, however, may not always be present on CT and severe mucosal thickening- though non-specific- is the most sensitive finding [20].
Granulomatosis with polyangiitis (GPA) can cause rhinosinusitis with nasal obstruction. As the disease becomes established, sinonasal erosion with osteitis and osteogenesis is common. There is a predilection for nasal septum involvement and perforation (Fig. 9) [11, 16]. Of note, T-cell variant of sinonasal lymphoma can be indistinguishable from GPA-associated rhinosinusitis [22]. Whilst cocaine-associated sinonasal disease can appear similar to GPA, unlike GPA it has a propensity to also cause soft and hard palate destruction [16].
Malignant sinonasal disease
Sinonasal cancers are uncommon and account for 3% of head and neck cancers. Head and neck cancers themselves represent just 1% of all cancers [23]. The clinical presentation is non-specific, and there is considerable overlap with inflammatory sinus disease, which can coexist. Anosmia is a late symptom, along with facial swelling, visual disturbance, and cranial nerve palsies [12]. Unfortunately, patients often present at an advanced stage of disease with invasion into surrounding structures [14].
Squamous cell carcinoma (SCC) is responsible for over 50% of sinonasal cancers [23] and is characterised by aggressive bone destruction, with necrotic soft tissue on CT. It typically affects the maxillary sinus unilaterally, or less commonly the nasal cavity where it may present clinically with a non-healing ulcer [24]. SCC has non-specific MRI characteristics exhibiting T1 isointensity, T2 intermediate, or slight T2 hyperintensity (Fig. 5), with moderate enhancement [12]. Human papillomavirus (HPV)-related SCC usually affects the nasal cavity and has an improved prognosis compared to non HPV-related SCC [25]. Synchronous nasopharyngeal SCC is possible, and the aerodigestive tract should routinely be reviewed [26].
Non-SCC sinonasal malignancies are much less common and include other epithelial cancers such as adenocarcinoma, minor salivary gland tumours, and non-epithelial tumours such as lymphoma and melanoma [23]. As with SCC, anosmia and olfactory dysfunction are typically late manifestations. Their imaging appearances can be indistinguishable from the more common SCC and may only be differentiated on histology (Fig. 4) [12].
Central sensorineural pathology
Congenital abnormalities
Unlike acquired causes of anosmia (detailed below), congenital anosmia is rare. A diagnosis of congenital anosmia can be made in patients with olfactory dysfunction confirmed on functional testing and with no recollection of ever having had smell sensation [6]. Congenital anosmia can be seen as part of a syndrome, or in the context of isolated congenital anosmia in which anosmia is the sole complaint [27].
MR imaging plays an important role in the diagnosis of congenital anosmia, not only for characterising any related syndromic anatomical deficits, but also in assessing the olfactory apparatus, or lack thereof. Congenital olfactory problems are characterised by any combination of: (1) olfactory tract and/or olfactory bulb volume reduction, or even complete absence (Fig. 10), and (2) normal, hypoplastic, or aplastic “flattening” of the olfactory sulci unilaterally or bilaterally (Fig. 11) [28]. Coronal T2 fat-saturated MRI sequences provide optimal imaging for identification of the olfactory sulci and for evaluation of the olfactory bulbs and tracts along their entire lengths (for comparison to normal MRI anatomy see Fig. 1).
Congenital anosmia can be associated disorders of the paramedian structures (including corpus callosal dysgenesis, hypothalamic and pituitary problems, lobar holoprosencephaly, and septo-optic dysplasia), as well as migrational abnormalities (polymicrogyria, pachygyria, and grey matter heterotopia) (Fig. 1) [29]. CHARGE syndrome (Coloboma, Heart defects, Atresia of the choanae, Retardation of growth, Genital and/or urinary abnormalities, Ear anomalies and/or deafness) is associated with both congenital anosmia, as well as olfactory problems arising from choanal atresia [29].
Kallmann syndrome specifically describes congenital anosmia with hypogonadotrophic hypogonadism and presents with delayed onset or absent puberty where anosmia can be an incidental finding in the clinical history. Kallmann syndrome results from a variety of genetic mutations, the most common of which demonstrates an X-linked pattern of inheritance [29].
Isolated congenital anosmia without endocrine disorder is more common compared to Kallmann syndrome [27, 30]. However, it is often not possible to discriminate true congenital anosmia from childhood acquired anosmia secondary to early viral infection or trauma [31]. Nonetheless, a depth of the olfactory sulcus of ≤ 8 mm has been suggested as specific for confirming isolated congenital anosmia [30].
Toxins and infection
Exposure to both viral infections and toxins has been associated with impairment of smell. Toxins account for an estimated 1–5% of all olfactory disorders and may be transient or permanent [32]. Postviral anosmia has recently become a topic of increased interest due to the COVID-19 pandemic, with anosmia having been reported as a common symptom of the infection [33]. Spontaneous recovery from postviral anosmia is seen in one-third of cases and can take up to 2 years [6]. It has been demonstrated that patients with postviral olfactory dysfunction have reduced olfactory bulb volumes on MRI compared to control groups [34]. Moreover, initial smaller olfactory bulb volumes at diagnosis may represent a poor prognostic marker for recovery of sense of smell – total olfactory bulb volumes of less than 40cm3 suggest a negligible chance of recovery [35].
Olfactory neuroblastoma
Primary tumours arising from the olfactory apparatus are rare. Olfactory neuroblastomas (or esthesioneuroblastomas) arise from the olfactory neuroepithelium and may lead to olfactory dysfunction [22]. However, patients more commonly present with nasal obstruction, epistaxis, and ocular disturbance. The tumour demonstrates a bimodal peak in the second and sixth decades [22]. Olfactory neuroblastomas are typically located at the olfactory neuroepithelium and are classically “dumbbell” shaped with the “waist” of the mass formed at the cribriform plate (Fig. 12) [22]. They demonstrate soft tissue density on CT and calcifications may be seen. On MRI, relative to grey matter, these tumours are isointense on T1, isointense-to-hyperintense on T2 weighted sequences, and enhance heterogeneously [22]. Olfactory neuroblastomas are slow-growing and often large at presentation with significant bony remodelling. However, destruction of the adjacent cribriform plate, fovea ethmoidalis, and lamina papyracea and extension into the anterior cranial fossa can also be present [11]. The intracranial extent is often better delineated on MRI than on CT. With intracranial extension, “capping cysts” at the margin between the tumour and the brain can often be identified (Fig. 10). The presence of intracranial “capping cysts” is highly suggestive of an olfactory neuroblastoma and is not seen in other anterior skull base lesions [36]. Lateral breach into the orbits, inferior extension into the nasal cavity, and posterior involvement of the sphenoid sinuses are all also frequently seen [22].
Olfactory groove meningiomas
Olfactory groove meningiomas account for 8–13% of intracranial meningiomas [37]. They tend to present with headache, visual disturbance, or frontal symptoms including dementia-type symptoms [37]. Olfactory groove meningiomas exhibit imaging features typical for a meningioma, including a CSF cleft, hyperostosis of the underlying bone, isointensity to grey matter on T1WI, iso-to-hyperintensity on T2 weighted imaging, and homogenous post-contrast enhancement (Fig. 13) [6, 37]. A small case series concluded that despite their close relation to the olfactory apparatus, olfactory groove meningiomas can but do not consistently cause hyposmia/anosmia [38]. In addition, when present, ansomia may not resolve with successful surgical resection. Furthermore, olfactory disturbance ipsilateral to the tumour location is a common sequelae post-resection [37]. Olfactory groove meningiomas are a common cause of the rare Foster Kennedy syndrome (direct optic nerve compression causing unilateral optic atrophy with contralateral papilloedema from raised intracranial pressure and anosmia).
Trauma
Trauma is a common cause of anosmia and symptomatic post-traumatic olfactory disturbance is strongly correlated with reduced olfactory bulb volumes [34, 35]. On CT assessment for post-traumatic olfactory symptoms, damage to the olfactory apparatus can be inferred by the presence of frontobasal contusions, whilst fractures of the cribriform plate are suggestive of damage to the fila olfactoria [10]. In some cases, a putative cause cannot be firmly identified on imaging, in which case shearing forces to the fila olfactoria and olfactory nerves at the cribriform plate may be responsible [28]. Acute CT imaging is very useful in identifying trauma-related surgical emphysema, pneumocephalus suggestive of anterior cranial fossa breach, and haemorrhagic or non-haemorrhagic traumatic contusions [39]. Where beam-hardening artefact may impede interpretation of haemorrhage at the anterior cranial fossa, blood sensitive MRI SWI sequences can be performed as an adjunct if necessary (Fig. 14).
CSF fistulas
The cribriform plate is a common site for acquired CSF fistula formation. A CSF fistula refers to an osteodural defect with consequent fistula formation [40]. This typically presents with CSF rhinorrhoea that can be exacerbated on vagal manoeuvres, and obstructive nasal symptoms with olfactory disturbance. 80% of acquired CSF fistulas are secondary to trauma, most commonly in the setting of anterior skull base fractures [41]. Less commonly, acquired CSF fistulas can arise secondary to iatrogenic causes, tumours, and chronically raised intracranial pressure [42]. Post-traumatic CSF leaks are generally small and can be managed conservatively with bed rest. However even if small, a persistent CSF leak places the patient at increased risk of meningitis and surgery may be required [40]. CT is the first-line to isolate the offending osteodural defect (Fig. 14) and does not require an active leak to be present unlike other imaging techniques (such as radionuclide imaging and CT cisternography) [42]. Though CT can detect even small osseous defects with a sensitivity of 92% and specificity of 100% [40, 42], a dural breach cannot be seen on CT. Isolating the specific site of a CSF fistula therefore becomes particularly problematic when there are numerous osseous defects, for example in the context of complex skull base trauma [42, 43].
Correlation with MRI is useful in demonstrating a dural breach, as inferred by high T2 signal CSF (from “meningocele” formation) (Fig. 15). Herniation of brain tissue (“meningoencephalocele”) can also be seen (Figs. 15d, 16), whilst subtle traction-related adjacent encephalomalacia and dural enhancement are both secondary signs of CSF fistula formation [42]. Heavily T2 weighted high spatial resolution CISS imaging provides optimal contrast between the CSF and the neighbouring brain and skull base and is a sensitive sequence for the detection of CSF fistulas [43]. However, CSF fistulas must be differentiated from sinusitis and other fluid intensity substances such as nasal secretions [42, 43]. Accurate localisation of the defect can direct endoscopic surgical repair, which carries reduced morbidity and is therefore being increasingly adopted over open repair [40].
Skull base and dural lesions
Intrinsic lesions of the anterior skull base can affect the olfactory epithelium, olfactory bulbs, and tracts. This includes osseous abnormalities such as Paget’s disease or fibrous dysplasia [11, 44]. Both of these pathologies produce expansile lesions that can encroach upon and obstruct the nasal cavity or anterior cranial fossa (Fig. 17) [16].
Neurodegenerative conditions
The traditional role of imaging in neurodegenerative disease is to map out the affected anatomical regions, assess brain volumes, and identify and exclude other competing or contributing pathologies. These include normal pressure hydrocephalus, ischaemia, or high burden of small vessel disease [2].
Olfactory disturbances can precede the onset of other symptoms in neurodegenerative diseases such as idiopathic Parkinson’s disease (IPD) and Alzheimer’s disease (AD) [6, 28]. Olfactory deficits, however, are also commonly seen as part of the normal ageing process [8]. Therefore, an emerging challenge for radiologists is to employ imaging techniques to help differentiate age-related olfactory deficits from an early manifestation of neurodegenerative disease, to facilitate earlier diagnosis.
Parkinson’s disease
Olfactory dysfunction in IPD is very common, occurring with the same frequency as resting tremor [45], and can precede motor symptom onset [46]. A marked loss of olfaction is interestingly not seen in benign essential tremor [47] or atypical Parkinsonism [48]. As such, olfactory dysfunction has been proposed as both a screening for IPD [49], and to clinically distinguish IPD from other competing differentials [48, 50, 51]. This is particularly relevant for atypical Parkinsonism, where the diagnosis can be challenging, with characteristic imaging findings only seen late in the disease [52].
Autopsy specimens have identified Lewy bodies- the pathological hallmark of the disease- within both the peripheral olfactory bulb and central cortical regions of the olfactory system [49]. However, there is lack of concordance in the literature as to whether olfactory bulb volumes are significantly reduced in IPD compared to control subjects [49, 53, 54], as it has been well-described that olfactory bulb volumes normally decrease with age [8]. Nevertheless, on a microstructural scale, diffusion tensor imaging can reveal increased diffusivity within the olfactory bulbs indicative of cellular degeneration in early IPD [55]. Moreover, MRI measurements of volume loss within the right piriform cortex in early IPD are correlated significantly with extent of olfactory dysfunction, when compared to age-matched controls [56].
Alzheimer’s disease
Olfactory dysfunction can occur early in AD and precede the onset of dementia [57]. This corresponds with the histopathological findings of neurofibrillary tangles (NFTs) within both the olfactory bulbs and tracts and centrally within the primary olfactory cortex [58]. This distribution of NFTs within the olfactory system is also seen in individuals with early AD [59]. Though the density of NFTs correlates with more severe disease, NFTs can also be present within the olfactory system as part of normal ageing [59]. Nevertheless, in patients with early AD, it has been found that functional MRI activity within the primary olfactory cortex [60] and the volume of olfactory bulb and tract on MRI [61] are significantly decreased when compared to age-matched control subjects.
Conclusion
The olfactory pathway represents a complex interplay between peripheral and central elements and is susceptible to myriad of different pathologies. Appropriate CT, MRI, or combined modality imaging can help to differentiate benign from malignant conditions, better characterise the nature of a lesion or disease process, and isolate the specific anatomical elements of the olfactory system that are involved.
Abbreviations
- AB
Amygdaloid body
- ACP
Anterior clinoid process
- AD
Alzheimer's disease
- ADC
Apparent diffusion coefficient
- CG
Crista galli
- CISS
Constructive interference in steady state
- COVID-19
Coronavirus disease 2019
- CP
Cribriform plate
- CSF
Cerebrospinal fluid
- CSF
Collateral sulcus
- CT
Computed tomography
- DWI
Diffusion weighted imaging
- EAC
Ethmoid air cells
- EC
Entorhinal cortex
- FE
Fovea ethmoidalis
- FLAIR
Fluid-attenuated inversion recovery
- GPA
Granulomatosis with polyangiitis
- GR
Gyrus rectus
- HPV
Human papillomavirus
- IIH
Idiopathic intracranial hypertension
- IPD
Idiopathic Parkinson's disease
- ITG
Inferior temporal gyrus
- LL
Lateral lamella
- LV
Lateral ventricles
- MRI
Magnetic resonance imaging
- MS
Maxillary sinus
- MTG
Middle temporal gyrus
- NFT
Neurofibrillary tangles
- OB
Olfactory bulb
- OC
Optic nerve canals
- OG
Orbital gyrus
- OR
Olfactory recess
- OS
Olfactory sulcus
- PC
Piriform cortex
- SC
Sinonasal compartment
- SCC
Squamous cell carcinoma
- SS
Sphenoid sinus
- SWI
Susceptibility weighted imaging
- T
Tesla
- T1WI
T1 weighted imaging
- T2WI
T2 weighted imaging
Authors’ contributions
Author 1 (G.L.): literature review; write up of the manuscript; image captions. Author 2 (A.W.): literature review; write up of the manuscript; image captions. Author 3 (T.C.): write up of the manuscript; identified suitable cases to illustrate learning points. Author 4 (A.A.): conceived idea for manuscript; write up of the manuscript; identified suitable cases to illustrate learning points; overall supervision of the writing of the manuscript. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction. Laryngoscope. 2004;114(10):1764–1769. doi: 10.1097/00005537-200410000-00017. [DOI] [PubMed] [Google Scholar]
- 2.Hawkes CH, Doty RL. The neurology of olfaction. Cambridge: Cambridge University Press; 2009. [Google Scholar]
- 3.Frasnelli J, Hummel T. Olfactory dysfunction and daily life. Eur Arch Otorhinolaryngol. 2005;262(3):231–235. doi: 10.1007/s00405-004-0796-y. [DOI] [PubMed] [Google Scholar]
- 4.López-Elizalde R, Campero A, Sánchez-Delgadillo T, Lemus-Rodríguez Y, López-González MI, Godínez-Rubí M. Anatomy of the olfactory nerve: a comprehensive review with cadaveric dissection. Clin Anat. 2018;31(1):109–117. doi: 10.1002/ca.23003. [DOI] [PubMed] [Google Scholar]
- 5.Hendrix P, Griessenauer CJ, Foreman P, Shoja MM, Loukas M, Tubbs RS. Arterial supply of the upper cranial nerves: a comprehensive review. Clin Anat. 2014;27(8):1159–1166. doi: 10.1002/ca.22415. [DOI] [PubMed] [Google Scholar]
- 6.Duprez TP, Rombaux P. Imaging the olfactory tract (Cranial Nerve #1) Eur J Radiol. 2010;74(2):288–298. doi: 10.1016/j.ejrad.2009.05.065. [DOI] [PubMed] [Google Scholar]
- 7.Cardali S, Romano A, Angileri FF, et al. Microsurgical anatomic features of the olfactory nerve: relevance to olfaction preservation in the pterional approach. Oper Neurosurg (Hagerstown). 2005;57(suppl_1):17–21. doi: 10.1227/01.NEU.0000144844.72403.7B. [DOI] [PubMed] [Google Scholar]
- 8.Buschhüter D, Smitka M, Puschmann S, et al. Correlation between olfactory bulb volume and olfactory function. Neuroimage. 2008;42(2):498–502. doi: 10.1016/j.neuroimage.2008.05.004. [DOI] [PubMed] [Google Scholar]
- 9.Burmeister HP, Bitter T, Heiler PM, et al. Imaging of lamination patterns of the adult human olfactory bulb and tract: in vitro comparison of standard- and high-resolution 3T MRI, and MR microscopy at 9.4T. NeuroImage. 2012;60(3):1662–1670. doi: 10.1016/j.neuroimage.2012.01.101. [DOI] [PubMed] [Google Scholar]
- 10.Hall JM, Powell J, Elbadawey MR, Birchall D, Zammit-Maempel I. Radiological appearances in olfactory dysfunction: pictorial review. J Laryngol Otol. 2015;129(6):529–534. doi: 10.1017/S0022215115001097. [DOI] [PubMed] [Google Scholar]
- 11.Francies O, Makalanda L, Paraskevopolous D, Adams A (2018) Imaging review of the anterior skull base. Acta Radiol Open 7(5). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977432/. Cited 1 Apr 2020 [DOI] [PMC free article] [PubMed]
- 12.Eggesbø HB. Imaging of sinonasal tumours. Cancer Imaging. 2012;7:136–152. doi: 10.1102/1470-7330.2012.0015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Rombaux P, Potier H, Bertrand B, Duprez T, Hummel T. Olfactory bulb volume in patients with sinonasal disease. Am J Rhinol. 2008;22(6):598–601. doi: 10.2500/ajr.2008.22.3237. [DOI] [PubMed] [Google Scholar]
- 14.Kawaguchi M, Kato H, Tomita H et al (2017) Imaging characteristics of malignant sinonasal tumors. J Clin Med 6(12). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742805/. Cited 22 May 2020 [DOI] [PMC free article] [PubMed]
- 15.Fatterpekar GM, Delman BN, Som PM. Imaging the paranasal sinuses: where we are and where we are going. Anat Rec (Hoboken) 2008;291(11):1564–1572. doi: 10.1002/ar.20773. [DOI] [PubMed] [Google Scholar]
- 16.Maroldi R, Ravanelli M, Borghesi A, Farina D. Paranasal sinus imaging. Eur J Radiol. 2008;66(3):372–386. doi: 10.1016/j.ejrad.2008.01.059. [DOI] [PubMed] [Google Scholar]
- 17.Gandhi D, Gujar S, Mukherji SK. Magnetic resonance imaging of perineural spread of head and neck malignancies. Top Magn Reson Imaging. 2004;15(2):79–85. doi: 10.1097/01.rmr.0000130601.57619.bd. [DOI] [PubMed] [Google Scholar]
- 18.Konstantinidis I, Triaridis S, Printza A, Vital V, Ferekidis E, Constantinidis J. Olfactory dysfunction in nasal polyposis: correlation with computed tomography findings. ORL J Otorhinolaryngol Relat Spec. 2007;69(4):226–232. doi: 10.1159/000101543. [DOI] [PubMed] [Google Scholar]
- 19.Gudziol V, Buschhüter D, Abolmaali N, Gerber J, Rombaux P, Hummel T. Increasing olfactory bulb volume due to treatment of chronic rhinosinusitis—a longitudinal study. Brain. 2009;132(11):3096–3101. doi: 10.1093/brain/awp243. [DOI] [PubMed] [Google Scholar]
- 20.Aribandi M, McCoy VA, Bazan C. Imaging features of invasive and noninvasive fungal sinusitis: a review. RadioGraphics. 2007;27(5):1283–1296. doi: 10.1148/rg.275065189. [DOI] [PubMed] [Google Scholar]
- 21.Philpott CM, Thamboo A, Lai L, et al. Olfactory dysfunction in allergic fungal rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2011;137(7):694–697. doi: 10.1001/archoto.2011.105. [DOI] [PubMed] [Google Scholar]
- 22.Dublin AB, Bobinski M. Imaging characteristics of olfactory neuroblastoma (Esthesioneuroblastoma) J Neurol Surg B Skull Base. 2016;77(1):1–5. doi: 10.1055/s-0035-1564053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Haerle SK, Gullane PJ, Witterick IJ, Zweifel C, Gentili F. Sinonasal carcinomas: epidemiology, pathology, and management. Neurosurg Clin N Am. 2013;24(1):39–49. doi: 10.1016/j.nec.2012.08.004. [DOI] [PubMed] [Google Scholar]
- 24.Das S, Kirsch CFE. Imaging of lumps and bumps in the nose: a review of sinonasal tumours. Cancer Imaging. 2005;5(1):167–177. doi: 10.1102/1470-7330.2005.0111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Chowdhury N, Alvi S, Kimura K, et al. Outcomes of HPV-related nasal squamous cell carcinoma. Laryngoscope. 2017;127(7):1600–1603. doi: 10.1002/lary.26477. [DOI] [PubMed] [Google Scholar]
- 26.Szewczyk-Bieda MJ, White RD, Budak MJ, Ananthakrishnan G, Brunton JN, Sudarshan TA. A whiff of trouble: tumours of the nasal cavity and their mimics. Clin Radiol. 2014;69(5):519–528. doi: 10.1016/j.crad.2013.12.004. [DOI] [PubMed] [Google Scholar]
- 27.Abolmaali ND, Hietschold V, Vogl TJ, Hüttenbrink K-B, Hummel T. MR evaluation in patients with isolated anosmia since birth or early childhood. Am J Neuroradiol. 2002;23(1):157–164. [PMC free article] [PubMed] [Google Scholar]
- 28.Yousem DM, Oguz KK, Li C. Imaging of the olfactory system. Semin Ultrasound CT MRI. 2001;22(6):456–472. doi: 10.1016/S0887-2171(01)90001-0. [DOI] [PubMed] [Google Scholar]
- 29.Booth TN, Rollins NK (2016) Spectrum of clinical and associated MR imaging findings in children with olfactory anomalies. Am J Neuroradiol. http://www.ajnr.org/content/early/2016/03/17/ajnr.A4738. Cited 22 May 2020 [DOI] [PMC free article] [PubMed]
- 30.Huart C, Meusel T, Gerber J, Duprez T, Rombaux P, Hummel T. The depth of the olfactory sulcus is an indicator of congenital anosmia. Am J Neuroradiol. 2011;32(10):1911–1914. doi: 10.3174/ajnr.A2632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Aiba T, Inoue Y, Matsumoto K, Shakudo M, Hashimoto K, Yamane H. Magnetic resonance imaging for diagnosis of congenital anosmia. Acta Otolaryngol Suppl. 2004;554:50–54. doi: 10.1080/03655230410018363. [DOI] [PubMed] [Google Scholar]
- 32.Upadhyay UD, Holbrook EH. Olfactory loss as a result of toxic exposure. Otolaryngol Clin N Am. 2004;37(6):1185–1207. doi: 10.1016/j.otc.2004.05.003. [DOI] [PubMed] [Google Scholar]
- 33.Xydakis MS, Dehgani-Mobaraki P, Holbrook EH et al (2020) Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis 0(0). https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30293-0/abstract. Cited 22 May 2020 [DOI] [PMC free article] [PubMed]
- 34.Mueller A, Rodewald A, Reden J, Gerber J, von Kummer R, Hummel T. Reduced olfactory bulb volume in post-traumatic and post-infectious olfactory dysfunction. NeuroReport. 2005;16(5):475–478. doi: 10.1097/00001756-200504040-00011. [DOI] [PubMed] [Google Scholar]
- 35.Rombaux P, Huart C, Deggouj N, Duprez T, Hummel T. Prognostic value of olfactory bulb volume measurement for recovery in postinfectious and posttraumatic olfactory loss. Otolaryngol Head Neck Surg. 2012;147(6):1136–1141. doi: 10.1177/0194599812459704. [DOI] [PubMed] [Google Scholar]
- 36.Som PM, Lidov M, Brandwein M, Catalano P, Biller HF. Sinonasal esthesioneuroblastoma with intracranial extension: marginal tumor cysts as a diagnostic MR finding. Am J Neuroradiol. 1994;15(7):1259–1262. [PMC free article] [PubMed] [Google Scholar]
- 37.Nakamura M, Struck M, Roser F, Vorkapic P, Samii M. olfactory groove meningiomas: clinical outcome and recurrence rates after tumor removal through the frontolateral and bifrontal approach. Neurosurgery. 2007;60(5):844–852. doi: 10.1227/01.NEU.0000255453.20602.80. [DOI] [PubMed] [Google Scholar]
- 38.Welge-Luessen A, Temmel A, Quint C, Moll B, Wolf S, Hummel T. Olfactory function in patients with olfactory groove meningioma. J Neurol Neurosurg Psychiatry. 2001;70(2):218–221. doi: 10.1136/jnnp.70.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Leboucq N, Menjot de Champfleur N, Menjot de Champfleur S, Bonafé A. The olfactory system. Diagn Interv Imaging. 2013;94(10):985–991. doi: 10.1016/j.diii.2013.06.006. [DOI] [PubMed] [Google Scholar]
- 40.Alonso RC, de la Peña MJ, Caicoya AG, Rodriguez MR, Moreno EA, de Vega Fernandez VM. Spontaneous skull base meningoencephaloceles and cerebrospinal fluid fistulas. RadioGraphics. 2013;33(2):553–570. doi: 10.1148/rg.332125028. [DOI] [PubMed] [Google Scholar]
- 41.Yilmazlar S, Arslan E, Kocaeli H, et al. Cerebrospinal fluid leakage complicating skull base fractures: analysis of 81 cases. Neurosurg Rev. 2006;29(1):64–71. doi: 10.1007/s10143-005-0396-3. [DOI] [PubMed] [Google Scholar]
- 42.Connor SEJ. Imaging of skull-base cephalocoeles and cerebrospinal fluid leaks. Clin Radiol. 2010;65(10):832–841. doi: 10.1016/j.crad.2010.05.002. [DOI] [PubMed] [Google Scholar]
- 43.Algin O, Hakyemez B, Gokalp G, Ozcan T, Korfali E, Parlak M. The contribution of 3D-CISS and contrast-enhanced MR cisternography in detecting cerebrospinal fluid leak in patients with rhinorrhoea. Br J Radiol. 2010;83(987):225–232. doi: 10.1259/bjr/56838652. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Borges A. Skull base tumours. Eur J Radiol. 2008;66(3):348–362. doi: 10.1016/j.ejrad.2008.01.018. [DOI] [PubMed] [Google Scholar]
- 45.Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis. 1975;28(9):493–497. doi: 10.1016/0021-9681(75)90058-2. [DOI] [PubMed] [Google Scholar]
- 46.Herting B, Schulze S, Reichmann H, Haehner A, Hummel T. A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol. 2008;255(3):367–370. doi: 10.1007/s00415-008-0665-5. [DOI] [PubMed] [Google Scholar]
- 47.Busenbark KL, Huber SJ, Greer G, Pahwa R, Koller WC. Olfactory function in essential tremor. Neurology. 1992;42(8):1631–1632. doi: 10.1212/WNL.42.8.1631. [DOI] [PubMed] [Google Scholar]
- 48.Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson’s disease. Neurology. 1993;43(5):962–965. doi: 10.1212/WNL.43.5.962. [DOI] [PubMed] [Google Scholar]
- 49.Wang J, You H, Liu J-F, Ni D-F, Zhang Z-X, Guan J. Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. Am J Neuroradiol. 2011;32(4):677–681. doi: 10.3174/ajnr.A2350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical Parkinsonian syndromes. Acta Neurol Scand. 1995;91(4):247–250. doi: 10.1111/j.1600-0404.1995.tb06998.x. [DOI] [PubMed] [Google Scholar]
- 51.Müller A, Müngersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci. 2002;9(5):521–524. doi: 10.1054/jocn.2001.1071. [DOI] [PubMed] [Google Scholar]
- 52.Meijer FJA, Aerts MB, Abdo WF, et al. Contribution of routine brain MRI to the differential diagnosis of parkinsonism: a 3-year prospective follow-up study. J Neurol. 2012;259(5):929–935. doi: 10.1007/s00415-011-6280-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Hummel T, Witt M, Reichmann H, Welge-Luessen A, Haehner A. Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson’s disease. J Neurol Sci. 2010;289(1–2):119–122. doi: 10.1016/j.jns.2009.08.026. [DOI] [PubMed] [Google Scholar]
- 54.Mueller A, Abolmaali ND, Hakimi AR, et al. Olfactory bulb volumes in patients with idiopathic Parkinson’s disease a pilot study. J Neural Transm (Vienna) 2005;112(10):1363–1370. doi: 10.1007/s00702-005-0280-x. [DOI] [PubMed] [Google Scholar]
- 55.Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease. J Neurol. 2011;258(7):1254–1260. doi: 10.1007/s00415-011-5915-2. [DOI] [PubMed] [Google Scholar]
- 56.Wattendorf E, Welge-Lüssen A, Fiedler K, et al. Olfactory impairment predicts brain atrophy in Parkinson’s disease. J Neurosci. 2009;29(49):15410–15413. doi: 10.1523/JNEUROSCI.1909-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Doty RL, Reyes PF, Gregor T. Presence of both odor identification and detection deficits in Alzheimer’s disease. Brain Res Bull. 1987;18(5):597–600. doi: 10.1016/0361-9230(87)90129-8. [DOI] [PubMed] [Google Scholar]
- 58.Attems J, Jellinger KA. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol. 2006;25(6):265–271. [PubMed] [Google Scholar]
- 59.Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging. 1991;12(4):295–312. doi: 10.1016/0197-4580(91)90006-6. [DOI] [PubMed] [Google Scholar]
- 60.Wang J, Eslinger PJ, Doty RL, et al. Olfactory deficit detected by fMRI in early Alzheimer’s disease. Brain Res. 2010;1357:184–194. doi: 10.1016/j.brainres.2010.08.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Thomann PA, Dos Santos V, Seidl U, Toro P, Essig M, Schröder J. MRI-derived atrophy of the olfactory bulb and tract in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2009;17(1):213–221. doi: 10.3233/JAD-2009-1036. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.